Cytochrome P450 enzyme, nucleic acid molecule, glycyrrhetinic acid derivative and application thereof
Through the in vitro enzyme catalytic conversion system of the cytochrome P450 enzyme CYP161H12, the problem of selective C-H bond activation of the B/D ring of glycyrrhizic acid was solved, and the efficient preparation and purification of glycyrrhizic acid derivatives were achieved, and its pharmacological research space was expanded.
Patent Information
- Application Number
- CN202411197628.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-19
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to realize the selective C-H bond activation of the B/D ring of glycyrrhizic acid through organic synthesis methods, and there are problems such as product background and difficulty in isolation and purification using whole-cell transformation using microbial organisms.
A cytochrome P450 enzyme CYP161H12 and its encoding gene are provided, and an in vitro enzyme catalytic transformation system is constructed to realize the activation of the B/D ring of the B/D ring of the glycyrrhizic acid skeleton molecule, and to prepare the glycyrrhizic acid derivative in combination with organic synthesis methods.
The highly selective C-H bond activation of the B/D ring of glycyrrhizic acid is achieved, the product spectrum is clean, and it is easy to be isolated and purified, expanding the biochemical space of glycyrrhizic acid derivatives, and in-depth exploration of the structure-effect relationship in pharmacological research.
Smart Images

Figure CN119060970A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of genetic engineering pharmaceuticals, and specifically relates to a cytochrome P450 enzyme, a nucleic acid molecule, a glycyrrhetinic acid derivative and applications thereof, and particularly relates to applications thereof in the preparation of novel glycyrrhetinic acid derivatives. Background Art
[0002] Glycyrrhetinic acid is a common oleanane-type pentacyclic triterpene natural product. Currently, a series of glycyrrhetinic acid derivatives obtained by structural modification of the glycyrrhetinic acid nucleus have shown a wide range of pharmacological activities in anti-inflammatory, anti-tumor, antiviral, and neuroprotective aspects. Traditional organic synthesis methods mainly include two methods: derivatization based on the hydroxyl group of the A ring, the conjugated enone of the C ring, and the C30 carboxyl group of the E ring on the glycyrrhetinic acid skeleton; or activation of the nearby CH bond based on the directing group strategy and derivatization, thereby improving its pharmacological activity. However, since the B and D rings of glycyrrhetinic acid are mostly sp 3 Due to the hybrid inert CH bond and the lack of directing groups, currently, it is impossible to achieve selective CH activation of glycyrrhetinic acid B / D ring through organic synthesis methods.
[0003] Cytochrome P450 enzymes (CYP450s for short) are a class of metalloenzymes with ferrous porphyrin as the catalytic center, which can catalyze the monooxygenation reaction of substrates with molecular oxygen as the oxidant. At the same time, the microenvironment formed by the interaction between different amino acid residues in the enzyme active pocket and the substrate gives CYP450s unique regio- and stereo-selectivity. For natural products with complex structures and multiple inert CH bonds with similar chemical environments, such as glycyrrhetinic acid, CYP450s are ideal catalysts for selective CH bond activation and hydroxylation.
[0004] Usually, CYP450s need reducing proteins to assist electron transfer and sufficient NADPH supply to perform monooxygenation reactions. Among them, the naturally fused P450RHF has an efficient electron transport chain, and its fused reducing protein P450RHFRed is highly compatible with many CYP450s. The artificial fusion enzyme CYP450-RHFRed has high catalytic efficiency and is easy to express and use. Opt13 is a phosphite dehydrogenase that can convert NADP to phosphite in a mild water system using Na2HPO3. + It is highly efficient in converting and recycling the expensive NADPH cofactor and is widely used in the catalytic transformations of CYP450s.
[0005] At present, the reported selective CH bond hydroxylation of glycyrrhetinic acid by enzyme catalysis is mainly through whole cell conversion, using enzymes of microorganisms such as bacteria Bacillus megaterium for catalysis. This method usually has a complex product background, which brings certain difficulties to separation and purification. Although the product spectrum of in vitro enzyme catalysis is clean and easy to promote on a large scale, there has been no report on the identification and cloning of bacterial CYP450 genes for selective CH bond hydroxylation of glycyrrhetinic acid. Summary of the invention
[0006] Purpose of the invention: The technical problem to be solved by the present invention is to provide a new cytochrome P450 enzyme or a catalytically active fragment thereof that can catalyze the selective CH bond hydroxylation of glycyrrhetinic acid.
[0007] The technical problem that the present invention needs to solve is to provide a nucleic acid molecule encoding the protein, as well as an expression cassette, a recombinant vector, a recombinant strain or a cell.
[0008] The technical problem that the present invention also solves is to provide an enzyme catalytic conversion system with CYP161H12 as a key catalytic enzyme, and to use the system for the in vitro bioconversion of different glycyrrhetinic acid derivatives.
[0009] The technical problem that the present invention also aims to solve is to provide the application of the cytochrome P450 enzyme or its catalytically active fragment, the nucleic acid molecule, the expression cassette, the recombinant vector, the recombinant strain or the cell, the recombinant vector, the recombinant strain, and the enzyme catalytic conversion system in the preparation of glycyrrhetinic acid derivatives.
[0010] The technical problem that the present invention needs to solve is to provide a series of new glycyrrhetinic acid derivatives.
[0011] The technical problem that the present invention also solves is to provide a method for preparing glycyrrhetinic acid derivatives by combining organic synthesis and enzyme catalysis.
[0012] The final technical problem to be solved by the present invention is to provide the use of glycyrrhetinic acid derivatives in the preparation of anti-inflammatory, anti-tumor, anti-viral or neuroprotective drugs.
[0013] Technical solution: To solve the above technical problems, the present invention provides a cytochrome P450 enzyme or a catalytically active fragment thereof, comprising:
[0014] (a) whose amino acid sequence is shown in SEQ ID NO: 2; or
[0015] (b) The amino acid sequence in (a) is substituted and / or deleted and / or one or more amino acids are added and has cytochrome P450 enzyme activity.
[0016] The present invention also includes a nucleic acid molecule encoding the cytochrome P450 enzyme or a catalytically active fragment thereof.
[0017] The nucleic acid molecule comprises:
[0018] (a) The cytochrome P450 enzyme or catalytically active fragment thereof encoded by the gene has a sequence identity of at least 70% with SEQ ID NO: 2.
[0019] (b) Its nucleotide sequence is shown in SEQ ID NO: 1.
[0020] The cytochrome oxidase gene of the present invention belongs to the CYP161H subfamily and is named CYP161H12 according to the international nomenclature of CYP450. The amino acid sequence (404aa) of the protein encoded by CYP161H12 is shown in the sequence table SEQ ID NO: 1, and its nucleotide sequence (1212bp) is shown in the sequence table SEQ ID NO. 2.
[0021] The CYP161H1 protein sequence was obtained from the NCBI database survey and screening, and CYP161H12 was derived from the actinomycete Amycolatopsis pretoriensis, and the amino acid sequence Uniprot number was A0A1H5RFX8. Codon preference was optimized according to the protein sequence, and the optimized sequence was shown in SEQ ID NO.2. The gene of the enzyme was then directly synthesized by Anhui General Biotechnology Co., Ltd. into the pET28a-RHFRed vector, and the restriction endonuclease cutting sites were NdeI and BamHI, respectively, to obtain the pET28a-CYP161H12-RHFRed recombinant plasmid.
[0022] The present invention also includes an expression cassette, a recombinant vector, a recombinant strain or a cell, which contains the nucleic acid molecule.
[0023] The present invention also includes a recombinant vector, which is obtained by introducing the nucleic acid molecule into an expression vector. Preferably, the expression vector includes a pET28a-RHFRed plasmid.
[0024] The present invention also includes a recombinant strain, which is obtained by introducing the recombinant vector into Escherichia coli. Preferably, the Escherichia coli includes Escherichia coli BL21.
[0025] The present invention also includes an enzyme-catalyzed conversion system, which includes a cell lysate 1 of the recombinant strain. Preferably, the cell-free catalytic system also includes a cell lysate 2 of a recombinant strain expressing phosphite dehydrogenase; preferably, the volume ratio of the cell lysate 1 to the cell lysate 2 is 2:1.
[0026] The present invention also includes the use of the cytochrome P450 enzyme or its catalytically active fragment, the nucleic acid molecule, the expression cassette, the recombinant vector, the recombinant strain or cell, the recombinant vector, the recombinant strain, and the enzyme catalytic conversion system in the preparation of glycyrrhetinic acid derivatives.
[0027] The present invention also includes a glycyrrhetinic acid derivative, the structural formula of which is shown below:
[0028]
[0029] in,
[0030] R1 is a functional group on the A ring of glycyrrhetinic acid or a derivative structure based on the modification of the A ring, wherein the functional group on the A ring includes a hydroxyl group at C3, an acetyl group at C3, a propionyl group at C3, a butyryl group at C3, and a keto carbonyl group at C3; the derivative structure based on the modification of the A ring includes an α, β-unsaturated ketone of a C3-oxo-C1-ene, an A ring expanded to form a seven-membered lactone ring, and a fused isoxazole heterocycle at C2 and C3, and R2 includes H, methyl or hexenyl.
[0031] Wherein, the glycyrrhetinic acid derivative has the following structural formula:
[0032]
[0033]
[0034] The present invention also includes a method for preparing glycyrrhetinic acid derivatives by combining organic synthesis and enzyme catalysis, comprising the following steps:
[0035] 1) Construction of a recombinant expression vector: introducing the nucleic acid or gene into an expression vector to obtain a recombinant expression vector;
[0036] 2) Obtaining and fermenting the recombinant strain: introducing the recombinant expression vector into the host bacteria to obtain the recombinant bacteria, fermenting and inducing the expression of the obtained recombinant bacteria and ultrasonically disrupting the obtained recombinant bacteria to obtain cell lysate 1; preferably, the process further includes fermenting and inducing the expression of the recombinant strain expressing phosphite dehydrogenase and ultrasonically disrupting the obtained recombinant bacteria to obtain cell lysate 2;
[0037] 3) Catalyzing the substrate to prepare glycyrrhetinic acid derivatives: reacting cell lysate 1 with the substrate to obtain; preferably, adding cell lysate 2 to react; preferably, the substrate includes glycyrrhetinic acid, 3-hydroxyglycyrrhetinic acid, 3-acetylglycyrrhetinic acid, 3-propionylglycyrrhetinic acid, 3-butyrylglycyrrhetinic acid, 3-oxoglycyrrhetinic acid, 3-oxo-1-eneglycyrrhetinic acid, and a glycyrrhetinic acid derivative with a seven-membered lactone ring in ring A.
[0038] Preferably, the recombinant expression vector in step 1) includes pET28a-CYP161H12-RHFRed;
[0039] Preferably, the fermentation step in step 2) comprises: inoculating the recombinant Escherichia coli containing pET28a-CYP161H12-RHFRed into LB medium and culturing at 37°C to obtain a seed solution, adding a trace amount of metal salt solution and the above seed solution to TB medium, culturing at 37°C to the logarithmic growth phase, then adding IPTG and 5-ALA to induce the bacteria to express the CYP161H12-RHFRed fusion protein, inducing the culture at 18°C for 20 hours, and collecting the bacteria by centrifugation for in vitro catalytic reaction;
[0040] Preferably, the formula of the trace metal salt solution is: 50mM FeCl3, 20mM CaCl2, 10mMMnSO4, 10mM ZnSO4, 2mM CoSO4, 2mM CuCl2, 2mM NiCl2, 2mM Na2MoO4, 2mM H3BO3; preferably, the trace metal salt solution is added to the TB culture medium at a ratio of 0.1% v / v;
[0041] Preferably, the concentration of IPTG in the TB medium is 0.1 mM, and the concentration of 5-ALA in the TB medium is 0.5 mM.
[0042] The present invention also includes constructing a multi-enzyme catalytic conversion system with CYP161H12 as a key catalyst and further preparing a glycyrrhetinic acid derivative, which specifically includes the following steps:
[0043] (1) Heterologous expression of CYP161H12-RHFRed in Escherichia coli: The recombinant Escherichia coli containing pET28a-CYP161H12-RHFRed was inoculated into LB medium and cultured at 37°C to obtain a seed solution, and a trace amount of metal salt solution and the above seed solution were added to the TB medium. First, culture at 37°C until the logarithmic phase of growth, then add isopropyl-β-D-thiogalactoside (IPTG) and 5-aminolevulinic acid hydrochloride (5-ALA) to induce the bacteria to express CYP161H12-RHFRed fusion protein, and induce culture at 18°C for 20 hours. The bacteria were collected by centrifugation for in vitro catalytic reaction. The specific implementation method is shown in Example 1.
[0044] (2) Heterologous expression of opt13 in Escherichia coli: Use seamless cloning technology to connect opt13 and vector pETDuet to obtain recombinant plasmid pETDue-opt13, which is then transformed into Escherichia coli BL21. The recombinant Escherichia coli is inoculated into LB liquid culture medium and cultured at 37°C to obtain seed liquid, and the above seed liquid is added to TB culture medium. First, culture at 37°C to the logarithmic phase of growth, then add isopropyl-β-D-thiogalactoside (IPTG) to induce the bacteria to express opt13, and induce culture at 18°C for 20 hours. Collect the bacteria by centrifugation for in vitro catalytic reaction. See Example 2 for specific implementation methods.
[0045] (3) In vitro catalytic conversion reaction: The fermented bacteria obtained in the above steps (1) and (2) were resuspended in kpi buffer and then ultrasonically disrupted to obtain cell lysates of CYP161H12-RhfRed and opt13, respectively. The two were combined in a volume ratio of 2:1 to obtain a three-component in vitro catalytic system including cytochrome oxidase CYP161H12, reducing protein RHFRed and phosphite dehydrogenase opt13 for efficient NADPH supply. Substrate, Na2HPO3·5H2O and NADP were added to the three-component catalytic system. + After reacting at 23°C for 20 hours, the reaction product was extracted and concentrated to separate the oxidation product of the hydroxylation of the inert CH bond on the B / D ring.
[0046] The composition of the kpi buffer solution in the above step (3) is 10.27 g K2HPO4·3H2O and 0.68 g KH2PO4 dissolved in 1 L distilled water to obtain a phosphate buffer solution with a pH of 7 and a concentration of 0.1 M.
[0047] The concentration of the kpi buffer described in step (3) above is preferably 0.1 M, and the pH value is preferably 7.0.
[0048] The novel glycyrrhetinic acid derivatives of the present invention can first be synthesized by organic chemistry to obtain glycyrrhetinic acid A-ring derivatives, and then catalyzed by CYP161H12 to obtain glycyrrhetinic acid derivatives in which the A-ring is derivatized and the B-ring and / or D-ring undergo CH bond hydroxylation, as shown in reaction scheme 1.
[0049] Reaction Scheme 1:
[0050]
[0051] In reaction route 1, the derivatives obtained after modification of the glycyrrhetinic acid A ring have different catalytic oxidation efficiencies from those of CYP161H12. Some derivatives can only obtain hydroxylated products at the C7β position, such as Examples 8 and 9; some derivatives can further obtain dihydroxyl products in which C7β and C15α undergo oxidation cascade, such as Examples 7, 10, 11, 12, and 13.
[0052] The novel glycyrrhetinic acid derivatives of the present invention can also first be hydroxylated by CYP161H12-catalyzed C7β of the B ring and / or C15α of the D ring of glycyrrhetinic acid, and then esterified at the C30 position of the glycyrrhetinic acid skeleton by organic chemical synthesis to obtain a product in which the C30 position carboxyl group is esterified and the B ring and / or the D ring undergo CH bond hydroxylation, as shown in route reaction route 2.
[0053] Reaction Scheme 2:
[0054]
[0055] In reaction route 2, CYP161H12 can undergo an oxidation cascade reaction on C7β and C15α of glycyrrhetinic acid to generate two hydroxylated products, and the esterification reaction on the carboxyl group can be easily prepared without affecting the existing hydroxyl groups.
[0056] The present invention also includes the use of the glycyrrhetinic acid derivatives in the preparation of anti-inflammatory, anti-tumor, anti-viral or neuroprotective drugs.
[0057] Beneficial effects: Compared with the prior art, the present invention has the following advantages:
[0058] ① The present invention provides a novel cytochrome oxidase CYP161H12 and its encoding gene. By using an in vitro catalytic conversion system constructed by CYP161H12, highly selective CH bond activation of the B ring and / or D ring of the glycyrrhetinic acid skeleton molecule is achieved. ② Compared with traditional organic synthesis, the CH bond hydroxylation achieved by the present invention using enzyme catalysis technology has obvious advantages. This technology not only performs well in site and stereoselectivity, but also has mild reaction conditions, is environmentally friendly, and complies with the principles of green chemistry. ③ Compared with microbial whole cell transformation, the enzyme in vitro catalytic conversion system constructed by the present invention can produce a clean product spectrum, which is conducive to the separation and purification of the product. ④ As a common molecular handle, hydroxyl groups are easily further modified to introduce other functional groups. The novel glycyrrhetinic acid derivatives synthesized in the present invention retain the hydroxyl groups on the B ring and the D ring. This is of great significance for expanding the biochemical space of glycyrrhetinic acid derivatives and in-depth exploration of their structure-activity relationship in pharmacological research. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 Schematic diagram of the in vitro catalytic conversion system of glycyrrhetinic acid using CYP161H12 as the key catalyst;
[0060] Figure 2 H NMR spectrum of compound 2b ( 1 H NMR spectrum);
[0061] Figure 3 The C NMR spectrum of compound 2b ( 13 C NMR spectrum);
[0062] Figure 4 H NMR spectrum of compound 3a ( 1 H NMR spectrum);
[0063] Figure 5 The C NMR spectrum of compound 3a ( 13 C NMR spectrum);
[0064] Figure 6 H NMR spectrum of compound 4a ( 1 H NMR spectrum);
[0065] Figure 7 The C NMR spectrum of compound 4a ( 13 C NMR spectrum);
[0066] Figure 8 H NMR spectrum of compound 5b ( 1 H NMR spectrum);
[0067] Fig. 9 The C NMR spectrum of compound 5b ( 13 C NMR spectrum);
[0068] Fig.10 H NMR spectrum of compound 6a ( 1 H NMR spectrum);
[0069] Fig.11 The C NMR spectrum of compound 6a ( 13 C NMR spectrum);
[0070] Fig.12 H NMR spectrum of compound 6b ( 1 H NMR spectrum);
[0071] Fig.13 The C NMR spectrum of compound 6b ( 13 C NMR spectrum);
[0072] Fig.14 H NMR spectrum of compound 7a ( 1 H NMR spectrum);
[0073] Fig.15 The C NMR spectrum of compound 7a ( 13 C NMR spectrum);
[0074] Fig.16 H NMR spectrum of compound 7b ( 1 H NMR spectrum);
[0075] Fig.17 The C NMR spectrum of compound 7b ( 13 C NMR spectrum);
[0076] Fig.18 H NMR spectrum of compound 8a ( 1 H NMR spectrum);
[0077] Fig.19 The C NMR spectrum of compound 8a ( 13 C NMR spectrum);
[0078] Fig. 20 H NMR spectrum of compound 8b ( 1 H NMR spectrum);
[0079] Fig.21 The C NMR spectrum of compound 8b ( 13 C NMR spectrum);
[0080] Fig. 22 H NMR spectrum of compound 9a ( 1 H NMR spectrum);
[0081] Fig.23 The C NMR spectrum of compound 9a ( 13 C NMR spectrum);
[0082] Fig.24 H NMR spectrum of compound 9b ( 1 H NMR);
[0083] Fig.25 The C NMR spectrum of compound 9b ( 13 C NMR spectrum);
[0084] Fig.26 H NMR spectrum of compound 10a ( 1 H NMR spectrum);
[0085] Fig. 27 The C NMR spectrum of compound 10a ( 13 C NMR spectrum);
[0086] Fig.28 The H NMR spectrum of compound 10b ( 1 H NMR spectrum);
[0087] Fig.29 The C NMR spectrum of compound 10b ( 13 C NMR spectrum). DETAILED DESCRIPTION
[0088] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0089] Example 1 Heterologous expression and fermentation of CYP161H12-RHFRed in Escherichia coli
[0090] 1. Obtain the pET28a-CYP161H12-RHFRed recombinant expression vector
[0091] CYP161H12 is derived from actinomycete Amycolatopsis pretoriensis, and the amino acid sequence Uniprot number is A0A1H5RFX8. CYP161H12 is optimized according to the codon preference of Escherichia coli to obtain the sequence of SEQ ID NO: 2. Using pET28a-RHFRed plasmid as an expression vector, CYP161H12 with a nucleotide sequence as shown in SEQ ID NO: 2 is inserted into the pET28a-RHFRed plasmid with restriction endonuclease cutting sites of NdeI and BamHI, and the recombinant vector pET28a-CYP161H12-RHFRed is directly synthesized by Anhui General Biological Company.
[0092] Among them, the synthesis process of pET28a-RHFRed is as follows: RHFRed is inserted into pET28a with restriction endonuclease cutting sites of BamHI and XhoI according to the amino acid sequence reported in the literature in 2020, and synthesized by Anhui General Biotechnology Co., Ltd. to obtain the vector pET28a-RHFRed. The amino acid sequence of RHFRed is SEQ NO: 3, and the gene sequence is SEQ NO: 4.
[0093] 2. Heterologous expression and fermentation of pET28a-CYP161H12-RHFRed
[0094] pET28a-CYP161H12-RHFRed was transformed into E. coli BL21, and the heterologously expressed BL21 monoclone was inoculated into 5 mL LB medium and cultured at 37°C and 220 rpm for 10 h. This was the seed solution. The seed solution was added to the sterilized TB medium at a 0.3% inoculation rate, and 50 μg / mL kanamycin and 1 mL / L trace metal salt solution (composition includes 50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, 2 mM H3BO3) were added thereto. The culture was continued at 37°C and 220 rpm until the OD value was 0.8. After cooling in an ice water bath for 20 min, 0.1 mM isopropyl-β-D-thiogalactoside (IPTG) and 0.5 mM 5-aminolevulinic acid hydrochloride (5-ALA) were added to induce the bacteria to express CYP161H12-RHFRed fusion protein, and the culture was induced at 18°C and 200 rpm for 20 h. The CYP161H12-RHFRed protein expressing bacteria were collected by centrifugation at 3750 rpm for 5 min for in vitro catalytic reaction.
[0095] Example 2 Expression and fermentation of phosphite dehydrogenase opt13 in Escherichia coli
[0096] 1. Construction of pRSFDuet-opt13 recombinant expression vector
[0097] The pETDuet plasmid (purchased from Anhui General Biotechnology Co., Ltd.) was used as a vector. The opt13 gene (the amino acid and gene sequence of the opt13 gene are shown in SEQ NO 5 and SEQ NO 6, synthesized by Anhui General Biotechnology Co., Ltd.) was inserted into the restriction endonuclease cutting sites PstI and HindIII of the vector, and the primers were forward: TCGAGCTCGGCGCGCCTGCAGCTGCCGAAACTCGTTATAACTCAC; reverse: GCATTATGCGGCCGCAAGCTTTTATCAGTCTGCGGCAGGATTG. The linearized vector and the gene obtained by PCR cloning were mixed in a ratio of 1:2, connected together under the action of homologous recombinase, and transformed into Escherichia coli DH5α for expression. The single clone was cultured in LB solid medium, the single clone was cultured, the plasmid was extracted, and the correct pETDuet-opt13 recombinant expression vector was constructed by sequencing.
[0098] 2. Heterologous expression and fermentation of pRSFDuet-opt13
[0099] The pETDuet-opt13 recombinant expression vector was transformed into Escherichia coli BL21, and the heterologously expressed BL21 monoclone was inoculated into 5 mL LB medium and cultured at 37°C and 220 rpm for 10 hours. This was the seed solution. The seed solution was added to the sterilized TB medium at a 0.3% inoculation rate, and 100 μg / mL ampicillin was added thereto. Cultured at 37°C and 220 rpm until the OD value was 0.8. After cooling in an ice water bath for 20 minutes, 0.1 mM isopropyl-β-D-thiogalactoside (IPTG) was added thereto to induce the bacteria to express the protein opt13, and the culture was induced at 18°C and 200 rpm for 20 hours. The opt13 protein-expressing bacteria were collected by centrifugation at 3750 rpm for 5 minutes for in vitro catalytic reaction.
[0100] Example 3 Construction of CYP161H12 cell-free catalytic system
[0101] The CYP161H12-RHFRed cells collected in Example 1 and the opt13 cells collected in Example 2 were resuspended in 0.1M, pH=7.0kpi buffer to OD600=30 and then ultrasonically disrupted to obtain cell lysates of CYP161H12-RHFRed and opt13, respectively, which were mixed at a volume ratio of CYP161H12-RHFRed:opt13=2:1 to form a cell-free catalytic system, wherein CYP161H12-RHFRed is a reaction catalyst.
[0102] Example 4 Preliminary screening and evaluation of the catalytic ability of CYP161H12 on different substrates
[0103] 3.33 mL of the CYP161H12-RHFRed cell lysate of Example 3 and 1.67 mL of the opt13 cell lysate were mixed and added to a glass tube, and substrates (glycyrrhetinic acid, 3-hydroxyglycyrrhetinic acid, 3-acetylglycyrrhetinic acid, 3-propionylglycyrrhetinic acid, 3-butyrylglycyrrhetinic acid, 3-oxoglycyrrhetinic acid, 3-oxo-1-enoylglycyrrhetinic acid, and glycyrrhetinic acid derivatives with a seven-membered lactone ring in ring A) (2 mM, 1.0 equiv.) and NADP pre-dissolved in 5% (v / v) DMSO were added thereto. + (0.5 equiv.) and Na2HPO3·5H2O (50 equiv.). After reacting at 23°C and 220 rpm for 20 h, the mixture was extracted with 1 mL of ethyl acetate and centrifuged at 10,000 rpm for 3 min. The organic solvent was removed from the supernatant and the remaining sample was dissolved in methanol for liquid phase analysis. The protein concentration of CYP161H12-RHFRed in this reaction was 3.68×10 -3 mM, the amount of catalyst used is 0.18 mol%.
[0104] Example 5 Large-scale preparation of enzyme-catalyzed oxidation products
[0105] In Example 4, the substrates that produce oxidation products were screened and amplified according to the method of Example 3. CYP161H12-RHFRed was a fermentation cell obtained from 2L TB culture medium, and opt13 was a fermentation cell obtained from 1L TB culture medium. They were mixed to obtain a cell-free catalytic system for large-scale preparation. 1 equiv. substrate pre-dissolved in DMSO, 50 equiv. Na2HPO3·5H2O and 0.5 equiv. NADP were added to the cell-free catalytic system. + After reacting for 20 hours at 23°C and 220 rpm, the reaction product was extracted three times with ethyl acetate, concentrated, separated and purified to obtain the oxidation product. For specific catalytic experiments, see the following examples.
[0106] The formula of TB medium is as follows: 2.2g KH2PO4 and 12.3g K2HPO4·3H2O are dissolved in 0.05L distilled water and sterilized at 121℃ for 20 minutes as a phosphorus source. 11.8g tryptone, 23.6g yeast extract, 4mL glycerol are dissolved in 0.95L distilled water, sterilized at 121℃ for 20 minutes and then cooled to 60℃, and 0.05L sterilized phosphorus source is added thereto to obtain 1LT TB medium.
[0107] Example 6 Preparation of glycyrrhetinic acid oxidation products by in vitro enzyme-catalyzed conversion
[0108] According to the method of Example 4, the yield of substrate 1 catalyzed by CYP161H12 was determined to be as high as 100%. The hydroxylation product 1a:1b was 39:61. According to the method of Example 5, 1a and 1b were prepared with 1g of glycyrrhetinic acid. The obtained structural data were consistent with the reported structural data after detection by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum.
[0109]
[0110] Compound 1a: 1 H NMR (400 MHz, DMSO-d6)δ H 5.43(1H,s,H-12),3.87(1H,dd,J=10.7,4.7Hz,H-3),3.01(1H,dd,J=4.5,11.4 Hz,H-7),2.26(1H,s,H-9),1.39,1.10,1.02,1.00,0.91,0.76,0.68(s,3H×7); 13 C NMR (100 MHz, DMSO-d6)δ C 199.1,178.2,170.2,127.9,77.0,71.2,61.8,51.3,50.4,49.2,44.8,43.6,41.3,38.9,37.9,37.1,3 6.7,32.0,30.8,30.0,28.9,28.8,28.6,28.3,27.5,26.6,23.6,16.5,16.4,12.7; HRESIMS(m / z)[M+H] + calculated C 30 H 47 O5 487.3423, found 487.3438.
[0111] Compound 1b: 1 H NMR (300MHz, Pyridine-d5)δ H6.18(1H,s,H-12),4.68(1H,m,H-15),4.51(1H,m,H-7),3.51(1H,m,H-3),1.74,1.46,1.42,1.35,1.28,1.09,0.89(s,3H×7); 13 CNMR (75MHz, Pyridine-d5)δ C 198.8,179.0,170.2,129.1,77.5,71.4,66.4,62.4,51.9,51.7,50.3,49.7,43.9,41.3,39.4,39.4,3 7.9,37.7,35.9,32.2,31.3,29.2,28.6,28.5,28.0,27.8,18.7,16.5,16.4,13.2; HRESIMS(m / z)[M+H] + calculated C 30 H 47 O6 503.3373, found 503.3408.
[0112] Example 7 Synthesis of 2a and 2b by Enzymatic Combination with Organic Catalysis
[0113] Step A: Synthesis of Substrate 2
[0114] 0.5 g (1 equiv.) of glycyrrhetinic acid was dissolved in 10 mL of acetic anhydride, heated under reflux at 130°C for 1 h, and then 5 mL of acetic acid was added thereto. After the reaction solution was cooled, ice water was added thereto to quench the reaction, and the filter cake was filtered and dried to obtain 0.45 g of substrate 2 (white solid, yield 82%). The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0115]
[0116] 1 H NMR (400MHz,CDCl3):δ H 5.74(1H,s,H-12),4.53(1H,dd,J=4.8,11.6Hz,H-3),2.39(1H,s,H-9),2.08(3H,s, CH3 C=O),1.38,1.25,1.18,1.15,0.90,0.90,0.86(3H,s,CH3×7); 13 C NMR (101MHz,CDCl3):δ C200.4,181.8,171.1,169.6,128.4,80.6,61.7,55.0,48.3,45.5,43.8,43.2,40.8,38.8,38.1,37.7,36.9,3 2.7,31.9,30.9,28.6,28.5,28.1,26.5,26.4,23.6,23.4,21.4,18.7,17.4,16.7,16.4; HRESIMS(m / z)[M+H] + calculatedC 32 H 49 O5 513.3580, found 513.3584.
[0117] Step B: Enzymatic synthesis of 2a and 2b
[0118] According to the method of Example 4, the yield of substrate 2 catalyzed by CYP161H12 was determined to be 92%. The ratio of hydroxylated product 2a:2b was 91:9. According to the method of Example 5, 0.2 g of substrate 2 was used to prepare 2a and 2b. Among them, compound 2a was detected by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the structural data obtained were consistent with the reported structural data. Compound 2b was reported for the first time in the present invention.
[0119]
[0120] Compound 2a: 1 H NMR (400MHz,CDCl3):δ H 5.78(1H,s,H-12),4.52(1H,dd,J=4.9,11.4Hz,H-3),4.10(1H,dd,J=4.9,10.8Hz,H-7),2.34(1H,s,H-9),2.07(3H,s, CH3 C=O),1.46,1.25,1.18,1.16,0.91,0.89,0.86(3H,s,CH3×7); 13 C NMR (101MHz,CDCl3):δ C 199.3,181.7,171.1,169.3,128.6,80.3,72.4,61.9,51.7,50.5,48.8,44.5,43.9,41.0,38.4,37.8,37.6,3 7.0,31.8,30.9,30.1,28.7,28.5,28.5,28.0,26.6,23.7,23.5,21.3,16.7,16.1,12.3; HRESIMS(m / z)[M+H] +calculated C 32 H 49 O6 529.3529, found 529.3533. Compound 2b: 1 H NMR (400MHz, Pyridine-d5):δ H 6.13(1H,s,H-12),4.76(1H,dd,J=5.2,10.9Hz,H-3),4.66(1H,m,H-15),4.44(1H,m,H-7),2.55(1H,s,H-9),2.04(3H,s, CH3 C=O),1.73,1.41,1.34,1.33,0.93,0.93,0.88(3H,s,CH3×7); 13 C NMR (101MHz, Pyridine-d5)δ C 198.5,179.1,170.3,170.3,129.0,80.1,71.1,66.4,62.1,51.7,51.6,50.3,49.7,43.8,41.3,38.6,37.9,3 7.8,37.4,35.9,32.2,31.3,29.1,28.5,27.9,27.3,23.8,20.9,18.7,16.8,16.2,13.2; HRESIMS(m / z)[M+H] + calculated C 32 H 49 O7 545.3478, found 545.3478.
[0121] Example 8 Synthesis of 3a by Enzymatic Combination with Organic Catalysis
[0122] Step A: Synthesis of substrate 3
[0123] 0.5 g (1 equiv.) of glycyrrhetinic acid was dissolved in 15 mL of anhydrous pyridine, and (1.2 equiv.) of propionic anhydride and (0.2 equiv.) of DMAP were added thereto. After heating and refluxing at 100°C for 3 h, the reaction solution was cooled, and ice water was added to quench the reaction. The reaction was filtered and the filter cake was dried to obtain 0.56 g of substrate 3 (white solid, yield 99%). The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0124]
[0125] 1 H NMR (300MHz,CDCl3):δ H5.73(1H,s,H-12),4.54(1H,dd,J=5.0,11.4Hz,H-3),1.39,1.24,1.18,1.14,0.89,0.88,0.84(3H,s,CH3×7); 13 C NMR (75MHz,CDCl3):δ C 200.4,181.7,174.4,169.6,128.4,80.3,61.7,55.0,48.2,45.5,43.8,43.2,40.9,38.7,38.1,37.7,36.9,32. 7,31.9,31.0,28.5,28.5,28.1,28.1,26.5,26.4,23.6,23.4,18.7,17.4,16.7,16.4,9.4; HRESIMS(m / z)[M+H] + calculated C 33 H 51 O5 527.3736, found527.3710.
[0126] Step B: Enzymatic synthesis of 3a
[0127] According to the method of Example 4, the yield of substrate 3 catalyzed by CYP161H12 was determined to be 61%. The hydroxylation product was 3a. According to the method of Example 5, 0.1 g of substrate 3 was used to prepare 3a. Compound 3a was reported for the first time in the present invention.
[0128]
[0129] Compound 3a: 1 H NMR (300 MHz, MeOD):δ H 5.65(1H,s,H-12),4.53(1H,dd,J=4.7,11.6Hz,H-3),4.07(1H,dd,J=5.0,10.8Hz ,H-7),2.47(1H,s,H-9),1.19,1.19,1.15,1.15,0.94,0.94,0.86(3H,s,CH3×7); 13 C NMR (75MHz, MeOD)δ C200.3,179.5,174.6,171.5,127.6,80.3,71.5,61.7,51.4,50.4,49.2,44.6,43.5,41.3,38.0,37.6,37.5,36. 8,31.5,30.7,29.7,27.9,27.8,27.5,27.4,27.1,26.3,23.1,22.6,15.8,15.3,11.6,8.3; HRESIMS(m / z)[M+H] + calculated C 33 H 51 O6 543.3686, found 543.3724.
[0130] Example 9 Synthesis of 4a by Enzymatic Combination with Organic Catalysis
[0131] Step A: Synthesis of substrate 4
[0132] 0.5 g (1 equiv.) of glycyrrhetinic acid was dissolved in 15 mL of anhydrous pyridine, and (1.2 equiv.) of n-butyric anhydride and (0.2 equiv.) of DMAP were added thereto. After heating and refluxing at 100°C for 3 h, the reaction solution was cooled, and ice water was added to quench the reaction. The reaction was filtered and the filter cake was dried to obtain 0.33 g of substrate 4 (white solid, yield 78%). The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0133]
[0134] 1 H NMR (400MHz,CDCl3):δ H 5.73(1H,s,H-12),4.55(1H,dd,J=4.8,11.6Hz,H-3),2.39(1H,s,H-9),1. 39,1.24,1.18,1.14,0.89,0.89,0.85(3H,s,CH3×7),0.97(3H,t,J=7.4Hz, CH3 CH2CH2C=O); 13 C NMR (101MHz,CDCl3):δ C200.5,182.1,173.6,169.6,128.4,80.3,61.7,55.0,48.2,45.5,43.8,43.2,40.8,38.8,38.1,37.7,36.9,36.8,3 2.7,31.9,30.9,28.6,28.5,28.1,26.5,26.4,23.6,23.4,18.7,18.7,17.4,16.8,16.4,13.8; HRESIMS(m / z)[M+H] + calculated C 34 H 53 O5:541.3893,found:541.3894.
[0135] Step B: Enzymatic synthesis of 4a
[0136] According to the method of Example 4, the yield of substrate 4 catalyzed by CYP161H12 was determined to be 23%. The hydroxylation product was 4a. According to the method of Example 5, 4a was prepared with 0.1 g of substrate 4. Compound 4a was reported for the first time in the present invention.
[0137]
[0138] Compound 4a: 1 H NMR (400 MHz, DMSO-d6):δ H 5.44(1H,s,H-12),4.45(1H,dd,J=4.4,11.8Hz,H-3),3.90(1H,dd,J=4.8,10.7Hz, H-7),1.40,1.06,1.00,0.96,0.83,0.82,0.73(3H,s,CH3×7),0.89(3H,t,J=7.3Hz, CH3 CH2CH2C=O); 13 C NMR (101 MHz, DMSO-d6):δ C 199.0,179.9,172.9,170.4,127.8,79.8,70.8,61.5,50.8,50.4,49.3,44.8,43.6,41.2,38.02,37.9,37.8,37.0, 36.3,32.0,30.8,30.0,28.8,28.6,28.3,28.1,26.6,23.8,23.5,18.6,17.1,16.4,13.9,12.7; HRESIMS(m / z)[M+H] + calculated C 34 H 53O6:557.3842,found:557.3872.
[0139] Example 10 Synthesis of 5a and 5b by Enzymatic Combination with Organic Catalysis
[0140] Step A: Synthesis of substrate 5
[0141] 0.5 g (1 mmol, 1 equiv.) of 1 was dissolved in 5 mL of THF, and then 1.5 mL of Jones reagent was added dropwise. After stirring for 1.5 h, the reaction solution changed from reddish brown to clear, and dark green solid blocks were present. After quenching with ice water, filtration and drying, 0.45 g of substrate 5 (white solid, yield 90%) was obtained. The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0142]
[0143] 1 H NMR (400MHz,CDCl3):δ H 5.77(1H,s,H-12),2.47(1H,s,H-9),1.40,1.30,1.25,1.19,1.13,1.09,0.88(s,CH3×7); 13 C NMR (101MHz,CDCl3):δ C 217.3,199.7,181.8,169.9,128.4,61.1,55.4,48.3,47.8,45.3,43.8,43.3,40.9,39.7,37.7,36 .7,34.3,32.1,31.9,30.9,28.6,28.5,26.5,26.4,26.4,23.4,21.5,18.8,18.5,15.7; LC-MS:[MH] - :467.4.
[0144] Step B: Enzymatic synthesis of 5a and 5b
[0145] According to the method of Example 4, the yield of substrate 5 catalyzed by CYP161H12 was determined to be 87%. The ratio of hydroxylated product 5a:5b was 76:24. According to the method of Example 5, 5a and 5b were prepared with 0.5 g of substrate 5. Among them, compound 5a was detected by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the structural data obtained were consistent with the reported structural data. Compound 5b was reported for the first time in the present invention.
[0146]
[0147] Compound 5a: 1H NMR (400MHz,CDCl3):δ H 5.80(1H,s,H-12),4.13(1H,t,J=7.9Hz,H-7),2.42(1H,s,H-9),1.46,1.29,1.24,1.20,1.12,1.07,0.87(s,CH3×7); 13 C NMR (101MHz,CDCl3):δ C 216.8,198.8,182.0,170.0,128.5,72.0,61.1,52.2,50.3,48.9,47.4,44.7,43.9,41.0,39.3,37.6,36 .7,34.2,31.8,30.9,30.1,29.9,28.6,28.5,26.6,26.3,23.59,21.45,15.4,12.2; HRESIMS(m / z)[M+H] + calculated C 30 H 45 O5 485.3267, found 485.3224.
[0148] Compound 5b: 1 H NMR (400MHz, Pyridine-d5):δ H 6.14(1H,s,H-12),4.64(1H,dd,J=5.0,11.4Hz,H-15),4.44(1H,dd,J=5.6,9.8 Hz,H-7),2.64(1H,s,H-9),1.69,1.41,1.41,1.34,1.18,1.07,0.88(s,CH3×7); 13 CNMR (101MHz, Pyridine-d5)δ C 215.3,198.1,178.9,170.6,128.9,70.6,66.5,61.4,51.8,51.5,50.3,49.7,47.3,43.8,41.3,39. 4,37.9,37.0,35.9,34.3,32.2,31.3,29.1,28.5,26.2,21.4,18.7,15.5,13.1; HRESIMS(m / z)[MH] - calculated C 30 H 43 O6 499.3060, found 499.3060.
[0149] Example 11 Synthesis of 6a and 6b by Enzymatic Combination with Organic Catalysis
[0150] Step A: Synthesis of substrate 6
[0151] 2 g (4.2 mmol, 1 equiv.) of compound 1 was dissolved in 60 mL of DMSO, and (4 equiv.) of 2-iodoacylbenzoic acid was added. After reflux reaction at 80 °C for 4 h, the mixture was cooled to room temperature, quenched with 5% NaHCO3, extracted with ether three times, and the organic layers were combined, washed with water and saturated sodium chloride solution, dried over anhydrous sodium sulfate, and the organic solvent was removed. The mixture was eluted with 200-300 mesh silica gel column chromatography (CH2Cl2:MeOH=20:1) to obtain 1.77 g of substrate 6 (white solid, yield 89%). The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0152]
[0153] 1 H NMR (400MHz,CDCl3):δ H 7.76(1H,d,J=10.2Hz,H-1),5.84(1H,d,J=10.2Hz,H-2),5.83(s,1H,H-12),1.44,1.42,1.26,1.21,1.18,1.13,0.89(CH3×7). 13 C NMR (101MHz,CDCl3):δ C 204.7,199.2,182.2,170.8,161.7,128.2,124.6,55.6,52.8,48.4,45.6,44.8,43.9,43.5,40.9,38 .8,37.7,32.1,31.9,30.9,28.6,28.5,27.6,26.5,26.3,23.4,21.6,20.1,19.0,18.2.LC-MS:[M+H] + :465.2.
[0154] Step B: Enzymatic synthesis of 6a and 6b
[0155] According to the method of Example 4, the yield of substrate 6 catalyzed by CYP161H12 was determined to be 81%. The hydroxylation product 6a:6b was 76:24. According to the method of Example 5, 6a and 6b were prepared with 0.2 g of substrate 6. Compounds 6a and 6b were reported for the first time in the present invention.
[0156]
[0157] Compound 6a: 11H NMR (400 MHz, MeOD): δ H 7.75 (1H, d, J = 10.2 Hz, H-1), 5.79 (1H, d, J = 10.2 Hz, H-2), 5.75 (1H, s, H-12), 4.13 (1H, m, H-7), 2.83 (1H, s, H-9), 1.52, 1.43, 1.21, 1.20, 1.18, 1.13, 0.88 (s, CH3×7); 13 13C NMR (101 MHz, MeOD) δ C 205.3, 199.0, 179.1, 172.5, 162.3, 127.4, 124.0, 70.9, 55.7, 50.5, 49.4, 49.0, 44.9, 44.1, 43.6, 41.1, 38.7, 37.6, 31.5, 30.6, 29.7, 28.6, 27.9, 27.4, 26.6, 26.3, 22.5, 20.7, 19.2, 12.0; HRESIMS (m / z) [M-H]- calculated C 30 H 41 O5 481.2954, found 481.2964.
[0158] Compound 6b: 1 1H NMR (400 MHz, MeOD): δ H 7.74 (1H, d, J = 10.3 Hz, H-1), 5.80 (1H, d, J = 10.4 Hz, H-2), 5.82 (1H, s, H-12), 4.34 (1H, dd, J = 5.2, 11.7 Hz, H-15), 4.17 (1H, dd, J = 5.2, 9.9 Hz, H-7), 2.79 (1H, s, H-9), 1.46, 1.43, 1.23, 1.21, 1.19, 1.15, 0.91 (s, CH3×7); 13 13C NMR (75 MHz, MeOD) δ C 205.2, 198.4, 179.0, 171.9, 162.2, 128.0, 124.0, 70.3, 66.3, 55.6, 51.2, 50.0, 49.6, 48.8, 44.1, 38.7, 37.3, 34.6, 31.7, 30.5, 30.4, 29.4, 28.4, 27.3, 26.8, 26.7, 20.6, 19.3, 17.2, 12.2; HRESIMS (m / z) [M-H]- calculated C 30 H 41O6 497.2903, found497.2924.
[0159] Example 12 Synthesis of 7a and 7b by Enzymatic Combination with Organic Catalysis
[0160] Step A: Synthesis of substrate 7
[0161] 0.5 g (1 mmol, 1 equiv.) of compound 5 was dissolved in 30 mL of anhydrous CH2Cl2, and (0.175 mmol) of m-chloroperbenzoic acid and (3.5 equiv.) of lithium carbonate were added. After stirring at room temperature for 12 h, the reaction was quenched with 5% Na2SO3, extracted with CH2Cl2 three times, and the organic layers were combined, washed with water, saturated NaHCO3 solution, and saturated sodium chloride solution, respectively, dried over anhydrous sodium sulfate, and the organic solvent was removed. 0.24 g of substrate 7 (white solid, yield 46%) was obtained by elution with 200-300 mesh silica gel column chromatography (petroleum ether: ethyl acetate = 2:1). The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0162]
[0163] 1 H NMR (400 MHz, DMSO-d6):δ H 5.46(1H,s,H-12),1.41,1.38,1.34,1.26,1.10,1.07,0.77(CH3×7). 13 CNMR (101MHz, DMSO-d6):δ C 198.5,178.2,175.0,170.5,127.9,85.5,61.2,52.5,49.0,48.5,45.3,43.6,43.5,41.1,39.5,38.0,3 2.5,32.0,31.8,31.4,30.8,28.9,28.3,26.6,26.5,26.2,23.3,22.1,18.3,18.0.LC-MS:[MH]-:483.3.
[0164] Step B: Enzymatic synthesis of 7a and 7b
[0165] According to the method of Example 4, the conversion rate of substrate 7 catalyzed by CYP161H12 was determined to be 87%. The ratio of hydroxylated product 7a:7b was 47:53. According to the method of Example 5, 7a and 7b were prepared with 0.2 g of substrate 7. Compounds 7a and 7b were reported for the first time in the present invention.
[0166]
[0167] Compound 7a: 1 H NMR (300 MHz, MeOD): δ H 5.70 (1H, s, H-12), 4.10 (1H, dd, J=4.4, 11.0 Hz, H-7), 5.75 (1H, s, H-12), 2.73 (1H, s, H-9), 1.53, 1.53, 1.46, 1.39, 1.19, 1.18, 0.87 (s, CH3×7); 13 C NMR (75 MHz, MeOD) δ C 199.1, 179.2, 176.8, 171.3, 127.9, 85.5, 70.5, 61.9, 50.3, 49.9, 49.4, 44.9, 43.6, 41.2, 39.4, 39.2, 37.5, 32.5, 31.7, 31.6, 30.6, 30.2, 29.7, 27.8, 27.4, 26.3, 25.5, 22.1, 17.1, 10.8; HRESIMS (m / z) [M-H] - calculated C 30 H 43 O6 499.3060, found 499.3060。
[0168] Compound 7b: 1 H NMR (300 MHz, MeOD): δ H 5.77 (1H, s, H-12), 4.28 (1H, dd, J=4.4, 11.0 Hz, H-15), 4.14 (1H, dd, J=5.2, 11.6 Hz, H-7), 2.70 (1H, s, H-9), 1.54, 1.48, 1.46, 1.39, 1.20, 1.20, 0.90 (s, CH3×7); 13 C NMR (101 MHz, MeOD) δ C 198.40, 178.9, 176.8, 170.8, 128.5, 85.4, 69.4, 66.2, 61.7, 51.2, 50.1, 49.5, 43.5, 40.8, 39.5, 39.3, 37.2, 34.7, 31.8, 31.7, 30.8, 30.5, 30.2, 29.4, 28.3, 27.3, 25.5, 17.1, 16.9, 11.0; HRESIMS (m / z) [M-H]-calculated C 30 H 43 O7 515.3009, found 515.3019。
[0169] Example 13 Synthesis of 8a and 8b by enzyme catalysis combined with organic catalysis
[0170] Step A: Synthesis of substrate 8
[0171] 0.5 g (1 mmol, 1 equiv.) of compound 2 was dissolved in 8 mL of DMF, and (3 equiv.) of potassium carbonate was added and stirred at room temperature for 0.5 h. Then (2 equiv.) of benzyl bromide was added dropwise, refluxed at 100 °C for 3 h, cooled, and then water was added to quench the reaction, filtered, and the filter cake was dried to obtain 0.53 g of white solid 8-S1. 8-S1 was dissolved in 8 mL of ethyl formate, and (16 equiv.) of sodium hydride was added. After stirring at room temperature for 10 min, methanol was added to quench the reaction, and extracted three times with a mixed organic solvent of CH2Cl2:Et2O of 1:2. The organic layers were combined, washed with 5% HCl, saturated NaHCO3 solution, and saturated sodium chloride solution, respectively, dried over anhydrous sodium sulfate, and the organic solvent was removed by rotary evaporation. 0.47 g of 8-S2 (white solid, total yield of two-step reaction was 79%) was obtained by elution with 200-300 mesh silica gel column chromatography (petroleum ether: ethyl acetate = 3:1). 0.47 g (0..8 mmol, 1 equiv.) of 8-S2 was dissolved in 10 mL of THF, to which 0.09 g of 10% Pd-C was added. After stirring at room temperature for 8 h in a hydrogen environment, Pd-C was removed by filtration with diatomaceous earth, the organic solvent was removed by rotary evaporation, and 0.22 g of 8-S3 (white solid, yield 56%) was obtained by elution with 200-300 mesh silica gel column chromatography (CH2Cl2:MeOH=30:1). 0.22 g (0.44 mmol, 1 equiv.) 8-S3 was dissolved in 5 mL acetic acid, and (5 equiv.) NH2OH·HCl and (0.5 equiv.) anhydrous sodium acetate were added thereto. The mixture was stirred at 60°C for 0.5 h and then cooled to room temperature. Ice water was added to quench the reaction and a white solid was precipitated. The filter cake was dried and eluted with 200-300 mesh silica gel column chromatography (CH2Cl2:MeOH=20:1) to obtain 0.17 g substrate 8 (white solid, yield 78%). The structural data obtained by mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum were consistent with the reported structural data.
[0172]
[0173] 1 H NMR (300MHz,CDCl3):δ H 8.04(1H,s,-CH=N-),5.82(1H,s,H-12),2.57(s,1H,H-9),1.42,1.35,1.27,1.27,1.21,1.13,0.89(CH3×7); 13 C NMR (101MHz,CDCl3):δ C199.7,182.2,172.3,170.2,150.4,128.5,109.1,60.1,53.3,48.2,45.3,43.9,43.4,41.0,38.4,37.7,36. 0,34.8,31.9,31.8,30.9,28.9,28.6,28.5,26.6,26.4,23.3,21.6,18.3,18.1,15.8; LC-MS:[MH]-:492.3.
[0174] Step B: Enzymatic synthesis of 8a and 8b
[0175] According to the method of Example 4, the yield of substrate 8 catalyzed by CYP161H12 was determined to be 97%. The hydroxylation product 8a:8b was 19:81. According to the method of Example 5, 8a and 8b were prepared with 0.2 g of substrate 8. Compounds 8a and 8b were reported for the first time in the present invention.
[0176]
[0177] Compound 8a: 1 H NMR (300MHz,CDCl3):δ H 8.03(1H,s,-CH=N-),5.85(1H,s,H-12),4.20(1H,dd,J=4.7,10.7Hz,H-7 ),2.52(1H,s,H-9),1.49,1.33,1.25,1.25,1.22,1.12,0.88(s,CH3×7); 13 C NMR (75MHz,CDCl3)δ C 198.7,182.0,171.9,170.0,150.3,128.6,109.2,71.9,60.1,50.4,50.3,48.9,44.7,43.9,41.1,38.4,37.6,35 .6,34.6,31.8,30.9,30.2,29.2,28.8,28.6,28.5,26.6,23.5,21.6,15.5,11.9; HRESIMS(m / z)[MH]-calculated C 31 H 42 NO5 508.3063, found 508.3064.
[0178] Compound 8b: 1 H NMR (300 MHz, MeOD):δ H8.15(1H,s,-CH=N-),5.78(1H,s,H-12),4.32(1H,dd,J=4.2,11.7Hz,H-15),4.17(1H,dd,J =4.5,11.1Hz,H-7),2.64(1H,s,H-9),1.47,1.36,1.27,1.22,1.20,1.12,0.90(s,CH3×7); 13 C NMR (101 MHz, MeOD)δ C 198.8,178.8,172.0,171.1,150.1,128.4,109.4,70.1,66.3,59.8,51.1,50.0,49.7,49.5,43.5,40.9,38.3,37 .3,34.9,34.7,34.2,31.7,30.6,28.5,27.8,27.4,26.8,20.8,17.3,14.7,11.6; HRESIMS(m / z)[MH]-calculated C 31 H 42 NO6 524.3012, found 524.3023.
[0179] Example 14: Synthesis of 9a and 9b by enzyme catalysis combined with organic catalysis
[0180] Step A: Synthesis of 9a
[0181] The enzyme catalytic product 1a in Example 6 was used as a raw material, 0.05 g (0.1 mmol, 1 equiv.) 1a was dissolved in 2 mL DMF, (4 equiv.) potassium carbonate was added thereto and stirred at room temperature for 30 min, and (2 equiv.) methyl iodide was added to the reaction solution. After stirring at room temperature for 2.5 h, water was added to precipitate a large amount of white solid, which was filtered, and the filter cake was collected and dried. The filter cake was eluted with 200-300 mesh silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 0.04 g of compound 9a (white powder, yield 78%).
[0182]
[0183] Compound 9a: 1 H NMR (300MHz,CDCl3):δ H5.72(1H,s,H-12),4.06(1H,dd,J=5.0,10.9Hz,H-7),3.24(1H,t,J=6.8Hz,H-3),3.7 0(3H,s,CH3),2.55(1H,s,H-9),1.45,1.16,1.15,1.15,1.03,0.82,0.82(s,CH3×7); 13 C NMR (75MHz,CDCl3)δ C 199.3,177.0,169.1,128.6,78.5,72.5,61.9,51.8,51.6,50.4,49.0,44.5,44.1,41.2,38.9,38.8,37.6 ,37.1,31.8,31.1,30.1,28.9,28.5,28.4,28.1,27.3,26.6,23.7,16.0,15.6,12.2; HRESIMS(m / z)[M+H] + calculated C 31 H 49 O5 501.3580, found 501.3545.
[0184] Step B: Synthesis of 9b
[0185] Using 1b in Example 6 as starting material, 9b (white powder, yield 49%) was obtained according to the esterification method in Step A of Example 14.
[0186]
[0187] Compound 9b: 1 H NMR (400MHz,pyridine-d5):δ H 6.06(1H,s,H-12),4.64(1H,dd,J=5.0,11.5Hz,H-15),4.49(1H,dd,J=4.5,10.8Hz,H-7),3.66(3H,s,OCH3 ),3.51(1H,dd,J=4.5,11.6Hz,H-3),2.48(1H,s,H-9),1.67,1.44,1.41,1.27,1.15,1.08,0.86(s,CH3×7); 13 C NMR (101MHz,pyridine-d5)δ C198.7,176.6,169.6,129.1,77.5,71.4,66.3,62.4,51.8,51.6,51.5,50.3,49.7,44.0,40.9,39.3,39.3,37.6 ,37.6,35.8,32.1,31.0,29.1,28.5,28.0,27.9,27.8,18.6,16.5,16.4,13.2; HRESIMS(m / z)[MH]-calculatedC 31 H 47 O6515.3373, found 515.3387.
[0188] Example 15 Synthesis of 10a and 10b by Enzymatic Combination with Organic Catalysis
[0189] Step A: Synthesis of 10a
[0190] Using compound 1a in Example 6 as a raw material, 0.04 g (0.8 mmol, 1 equiv.) of 1a was dissolved in 2 mL of DMF, and (3 equiv.) of potassium carbonate was added thereto and stirred at room temperature for 30 min. (1.5 equiv.) of 6-bromo-1-hexene was added to the reaction solution. After stirring at room temperature for 2.5 h, water was added to precipitate a large amount of white solid, which was filtered off by suction, and the filter cake was collected and dried. The filter cake was eluted with 200-300 mesh silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 0.035 g of compound 10a (white powder, yield 75%).
[0191]
[0192] Compound 10a: 1 H NMR (400 MHz, MeOD):δ H 5.04(1H,dd,J=1.7,17.1Hz,CH2=CHCH2-),4.98(1H,d,J=10.2Hz,CH2=CHCH2-),4.05(1H,dd,J=5.0,11.0Hz,H -7),3.19(1H,dd,J=4.5,11.7Hz,H-3),2.42(1H,s,H-9),1.50,1.17,1.16,1.14,1.03,0.85,0.83(s,CH3×7); 13 C NMR (101 MHz, MeOD):δ C200.3,176.7,170.9,138.1,127.8,114.0,77.8,71.7,64.1,62.0,51.5,50.4,49.2,44.6,43.9,41.1,38.6,38.6,37.5, 36.9,33.0,31.5,30.6,29.6,28.2,27.9,27.8,27.3,27.2,26.5,26.3,25.2,22.6,15.3,15.0,11.6; HRESIMS(m / z)[M+H] + calculated C 36 H 57 O5 569.4206, found 569.4190.
[0193] Step B: Synthesis of 10b
[0194] Using compound 1b in Example 6 as raw material, compound 10b (white powder, yield 43%) was obtained according to the esterification method in step A of Example 15.
[0195]
[0196] Compound 10b: 1 H NMR (300MHz,CDCl3):δ H 5.04(1H,m, CH2 =CHCH2-), 4.97(1H,m, CH2 =CHCH2-),4.31(1H,dd,J=4.2,11.8Hz,H-15),4.07(1H,dd,J=4.9,11.2Hz,H-7),3.21(1H,dd ,J=4.6,11.8Hz,H-3),2.37(1H,s,H-9),1.43,1.18,1.16,1.16,1.04,0.88,0.83(s,CH3×7); 13 C NMR (101 MHz, MeOD)δ C 199.5,176.6,170.3,138.1,128.4,114.0,77.7,71.0,66.2,64.1,61.8,51.3,51.2,49.8,49.5,43.8,40.7,38.6,38.6, 37.2,37.1,34.7,33.0,31.7,30.5,28.3,27.9,27.2,27.2,26.5,26.4,25.2,17.2,15.3,15.0,11.8; HRESIMS(m / z)[M+H] +calculated C 36 H 57 O6 585.4155, found 585.4154.
[0197] Example 16 Study on the pharmacological effects of the product of the present invention
[0198] In vitro antitumor activity screening assay
[0199] Step A: Cell culture
[0200] Human liver cancer cells HepG2 and human colon cancer cells SW480 were cultured in complete culture medium containing 10% (v / v) heat-inactivated fetal bovine serum, 100 U / mL penicillin, and 100 U / mL streptomycin in high-glucose DMEM culture medium. All cells used in experiments were cultured in a 37°C incubator with 5% CO2 saturated humidity.
[0201] Step B: Preparation of compound solutions at different concentrations
[0202] All compounds were dissolved in DMSO to prepare a final compound stock solution with a concentration of 20 mM.
[0203] The 200 μM compound solution was prepared by adding 10 μL of compound stock solution to 1 mL of complete medium;
[0204] The 80 μM compound solution was prepared by adding 4 μL of compound stock solution to 1 mL of complete medium;
[0205] The 40 μM compound solution was prepared by adding 0.5 mL of 80 μM compound solution to 0.5 mL of complete medium;
[0206] The 20 μM compound solution was prepared by adding 0.5 mL of 40 μM compound solution to 0.5 mL of complete medium;
[0207] The 10 μM compound solution was prepared by adding 0.5 mL of 20 μM compound solution to 0.5 mL of complete medium;
[0208] 5 μM compound solution was prepared by adding 0.5 mL of 10 μM compound solution to 0.5 mL of complete medium;
[0209] Step C: Preliminary screening of cell growth inhibitory activity
[0210] The inhibitory effect of the compound on tumor cells was investigated using the CCK8 method. A cell suspension of a certain density (5×10 4 / mL cells) were inoculated in a 96-well plate, of which 200 μL 0.01M, pH=7.4 PBS buffer was added to the outermost 36 wells of the 96-well plate, and the inner 60 wells were used as the drug group, blank group and negative control group. Each group was subjected to three parallel experiments.
[0211] Drug group: 100 μL of cell suspension was added to each well and incubated in an incubator for 24 h. 100 μL of 80 μM compound solution (100 μL of 200 μM compound solution was added to compound 1) was added and incubated for 48 h. 20 μL of CCK-8 was added to each well and incubated for another 2 h. The absorbance at 450 nm was detected using an ELISA reader.
[0212] Blank group: 100 μL complete medium was added to each well and incubated in an incubator for 24 h. After adding 100 μL complete medium and incubating for 48 h, 20 μL CCK8 was added to each well and incubated for another 2 h. The absorbance at 450 nm was detected using an enzyme reader.
[0213] Negative control group: 100 μL of cell suspension was added to each well and incubated in an incubator for 24 h. 100 μL of complete medium containing 0.4 μL DMSO was added and incubated for 48 h. 20 μL CCK8 was added to each well and incubated for another 2 h. The absorbance at 450 nm was detected using an enzyme reader.
[0214] The cell growth inhibition rate was calculated according to the following formula:
[0215]
[0216] IR:Inhibitory Ratio Cell growth inhibition rate
[0217] ODpositive: absorbance of the drug group
[0218] ODblank: absorbance of blank group
[0219] ODnegetive: absorbance of negative control group
[0220] Step D: Determination of IC50 of the half-maximal growth inhibition concentration of the compound on tumor cells HepG2 and SW480
[0221] For compounds with tumor cell inhibition rate higher than 50% at a concentration of 40 μM, the cell growth inhibition rate was tested at concentration gradients of 80 μM, 40 μM, 20 μM, 10 μM, and 5 μM, and three parallel groups were set for each concentration. According to the cell inhibition rate at different concentrations, the half growth inhibition concentration IC50 was calculated using GraphPad Prism9.
[0222] Table 1 IC50 (μmol / L) of compounds against HepG2 and SW480
[0223]
[0224] The in vitro antitumor activity screening experiment of a series of glycyrrhetinic acid derivatives containing B-ring and / or D-ring hydroxyl groups provided by the present invention showed that the activity of compound 10a against human colon cancer cells was more than twice that of the parent compound 1 glycyrrhetinic acid; the activity of compound 10b against human liver cancer cells and human colon cancer cells was more than twice that of the parent compound 1 glycyrrhetinic acid. The above results indicate that the products of selective CH bond hydroxylation at the C7β and C15α sites in the glycyrrhetinic acid structural skeleton obtained by using the cytochrome P450 enzyme-CYP161H12 provided by the present invention have potential antitumor activity, and it is expected to be possible to prepare novel antitumor active drugs based on derivatization of the hydroxylation sites.
Claims
1. A cytochrome P450 enzyme or a catalytically active fragment thereof, comprising: (a) the amino acid sequence of which is shown in SEQ ID NO: 2; or (b) The amino acid sequence in (a) is substituted and / or deleted and / or one or more amino acids are added and has cytochrome P450 enzyme activity.
2. A nucleic acid molecule encoding the cytochrome P450 enzyme or a catalytically active fragment thereof according to claim 1.
3. The nucleic acid molecule according to claim 2, comprising: (a) the sequence encoding the cytochrome P450 enzyme or the catalytically active fragment thereof according to claim 1 has at least 70% sequence identity with SEQ ID NO: 2; (b) Its nucleotide sequence is shown in SEQ ID NO:
1.
4. An expression cassette, a recombinant vector, a recombinant strain or a cell, comprising the nucleic acid molecule according to claim 2 or 3.
5. A recombinant vector or a recombinant strain, characterized in that: The recombinant vector is obtained by introducing the nucleic acid molecule described in claim 2 or 3 into an expression vector. Preferably, the expression vector includes a pET28a-RHFRed plasmid. The recombinant strain is obtained by introducing the recombinant vector described in claim 4 into Escherichia coli. Preferably, the Escherichia coli includes Escherichia coli BL21.
6. An enzyme-catalyzed conversion system, characterized in that: The enzyme-catalyzed conversion system comprises a cell lysate 1 of the recombinant strain according to claim 5. Preferably, the enzyme-catalyzed conversion system further comprises a cell lysate 2 of a recombinant strain expressing phosphite dehydrogenase; preferably, the volume ratio of the cell lysate 1 to the cell lysate 2 is 2:
1.
7. Use of the cytochrome P450 enzyme or catalytically active fragment thereof according to claim 1, the nucleic acid molecule according to claim 2 or 3, the expression cassette, recombinant vector, recombinant strain or cell according to claim 4, the recombinant vector, the recombinant strain according to claim 5, and the enzyme catalytic conversion system according to claim 6 in the preparation of glycyrrhetinic acid derivatives.
8. Glycyrrhetinic acid derivatives, the structural formula of which is shown below: in, R1 is a functional group on the A ring of glycyrrhetinic acid or a derivative structure based on the modification of the A ring, wherein the functional group on the A ring includes a hydroxyl group at C3, an acetyl group at C3, a propionyl group at C3, a butyryl group at C3, and a keto carbonyl group at C3; the derivative structure based on the modification of the A ring includes an α, β-unsaturated ketone of a C3-oxo-C1-ene, an A ring expanded to form a seven-membered lactone ring, and a fused isoxazole heterocycle at C2 and C3, and R2 includes H, methyl or hexenyl. Preferably, the glycyrrhetinic acid derivative has the following structural formula:
9. A method for preparing glycyrrhetinic acid derivatives by combining organic synthesis and enzyme catalysis, characterized in that: The following steps are involved: 1) Construction of a recombinant expression vector: introducing the nucleic acid or gene described in claim 2 or 3 into an expression vector to obtain a recombinant expression vector; 2) Obtaining and fermenting the recombinant strain: introducing the recombinant expression vector into the host bacteria to obtain the recombinant bacteria, fermenting and inducing the expression of the obtained recombinant bacteria and ultrasonically disrupting the obtained recombinant bacteria to obtain cell lysate 1; preferably, the process further includes fermenting and inducing the expression of the recombinant strain expressing phosphite dehydrogenase and ultrasonically disrupting the obtained recombinant bacteria to obtain cell lysate 2; 3) Catalyzing the substrate to prepare a glycyrrhetinic acid derivative: reacting the cell lysate 1 with the substrate to obtain; preferably, the process further comprises adding the cell lysate 2 to react; preferably, the substrate comprises glycyrrhetinic acid, 3-hydroxyglycyrrhetinic acid, 3-acetylglycyrrhetinic acid, 3-propionylglycyrrhetinic acid, 3-butyrylglycyrrhetinic acid, 3-oxoglycyrrhetinic acid, 3-oxo-1-eneglycyrrhetinic acid, and a glycyrrhetinic acid derivative in which the A ring is a seven-membered lactone ring; Preferably, the recombinant expression vector in step 1) includes pET28a-CYP161H12-RHFRed; Preferably, the fermentation step in step 2) comprises: inoculating the recombinant Escherichia coli containing pET28a-CYP161H12-RHFRed into LB medium and culturing at 37°C to obtain a seed solution, adding a trace amount of metal salt solution and the above seed solution to TB medium, culturing at 37°C to the logarithmic growth phase, then adding IPTG and 5-ALA to induce the bacteria to express the CYP161H12-RHFRed fusion protein, inducing the culture at 18°C for 20 hours, and collecting the bacteria by centrifugation for in vitro catalytic reaction; Preferably, the formula of the trace metal salt solution is: 50mM FeCl3, 20mM CaCl2, 10mM MnSO4, 10mM ZnSO4, 2mM CoSO4, 2mM CuCl2, 2mM NiCl2, 2mM Na2MoO4, 2mM H3BO3; preferably, the trace metal salt solution is added to the TB culture medium at a ratio of 0.1% v / v; Preferably, the concentration of IPTG in the TB medium is preferably 0.1 mM, and the concentration of 5-ALA in the TB medium is preferably 0.5 mM; Preferably, in the above step (3), the ratio of adding the cell lysis solution 1 to the cell lysis solution 2 is 2:
1.
10. Use of the glycyrrhizic acid derivative according to claim 8 in the preparation of anti-inflammatory, anti-tumor, antiviral or neuroprotective drugs.
